221 related articles for article (PubMed ID: 38066870)
1. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations.
Gill H; Leung GMK; Kwong YL
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):667-675. PubMed ID: 38066870
[TBL] [Abstract][Full Text] [Related]
2. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
3. New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.
Patel AB; Vellore NA; Deininger MW
Clin Cancer Res; 2016 Mar; 22(5):1037-47. PubMed ID: 26933174
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutics in myeloproliferative neoplasms.
Venugopal S; Mascarenhas J
J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
[TBL] [Abstract][Full Text] [Related]
6. Biology and therapeutic targeting of molecular mechanisms in MPNs.
How J; Garcia JS; Mullally A
Blood; 2023 Apr; 141(16):1922-1933. PubMed ID: 36534936
[TBL] [Abstract][Full Text] [Related]
7. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
8. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
Loscocco GG; Vannucchi AM
Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Stem Cell Transplantation in Myelofibrosis.
Jain T; Mesa RA; Palmer JM
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1429-1436. PubMed ID: 28499938
[TBL] [Abstract][Full Text] [Related]
10. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
Mesa RA; Passamonti F
Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
[TBL] [Abstract][Full Text] [Related]
11. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
12. A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.
Duminuco A; Torre E; Palumbo GA; Harrison C
Curr Hematol Malig Rep; 2023 Oct; 18(5):176-189. PubMed ID: 37395943
[TBL] [Abstract][Full Text] [Related]
13. Bomedemstat as an investigative treatment for myeloproliferative neoplasms.
Rienhoff HY; Gill H
Expert Opin Investig Drugs; 2023; 32(10):879-886. PubMed ID: 37804041
[TBL] [Abstract][Full Text] [Related]
14. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
Scherber RM; Mesa RA
Blood Rev; 2020 Jul; 42():100716. PubMed ID: 32593470
[TBL] [Abstract][Full Text] [Related]
15. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
16. Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.
Puglianini OC; Peker D; Zhang L; Papadantonakis N
Lab Med; 2023 Jan; 54(1):13-22. PubMed ID: 35960786
[TBL] [Abstract][Full Text] [Related]
17. Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.
Barosi G; Lupo L; Rosti V
Curr Hematol Malig Rep; 2012 Mar; 7(1):50-6. PubMed ID: 22278747
[TBL] [Abstract][Full Text] [Related]
18. Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.
Calabresi L; Balliu M; Bartalucci N
Methods Cell Biol; 2022; 171():81-109. PubMed ID: 35953207
[TBL] [Abstract][Full Text] [Related]
19. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibitors in the treatment of myelofibrosis.
Levavi H; Hoffman R; Marcellino BK
Clin Adv Hematol Oncol; 2022 Jul; 20(7):456-467. PubMed ID: 35802878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]